You are here

SARC024

Active
A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Type of Sarcoma: 
Refractory liposarcoma, osteogenic sarcoma, Ewing/Ewing-like sarcomas
Drug: 
Regorafenib and placebo (for Liposarcoma and Osteogenic Sarcoma only)
Accrual Status: 
Recruiting
Overall Study Principal Investigator: 
Robert Maki, MD, PhD
Professor Pediatrics, Hematology & Oncology
Hofstra-Northwell School of Medicine

 
Co-Principal Investigators: 
Richard F. Riedel, MD
Associate Professor of Medicine
Duke University School of Medicine

Christopher W. Ryan, MD
Medical Oncologist
Oregon Health and Science University

Steven Attia, DO
Medical Oncologist
Mayo Clinic

Lara E. Davis
Assistant Professor of Medicine
Oregon Health and Science University

Leo Mascarenhas, MD, MS
Pediatric Hematologist-Oncologist
Children's Hospital Los Angeles

For more information about this trial and open sites: